Autopsy report · NCT00750581

An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants

“Study medication was no longer available for study”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 years 5 months before it stopped.
• 9 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2, Phase 3

Sponsor

University of Calgary

Sponsor type

University, hospital or other

Conditions

Patent Ductus Arteriosus

Interventions

Indomethacin

Participants

9

Sites

1

Countries

Canada

Trials that died the same way

• CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma
  “Study drug no longer available” (89% match in meaning)
• Letrozole and Celecoxib in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
  “study drug unavailable” (82% match in meaning)
• P1101 in Treating Patients With Myelofibrosis
  “Study drug became commercially available” (75% match in meaning)
• Phase II Study of TPA Plus Dexamethasone & CMT in Hematologic Malignancies
  “Study was terminated early due to lack of experimental medication (supply issues)” (74% match in meaning)
• Exenatide For Reducing the Reinforcing Effects of Cocaine
  “The study was closed due to the inability to acquire the study drug.” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.